 VBI Vaccines recently reported updated data from their VBI-1901 candidate in recurrent Glioblastoma. The company publicized the median overall survival and 18-month overall survival data are outperforming historical controls. VBI-1901 is showing its ability to have an impact on the tumor response and clinical outcomes. One patient who is still on protocol has been progression-free for over two years. 